Abstract: Objective The aim of this study was to observe the clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury (DILI). Methods 90 patients with DILI were enrolled in our hospital between October 2017 and October 2020, and were randomly divided into control and observation group, with 45 cases in each group. The patients in the control group was treated with reduced glutathione, while those in the observation group was additionally treated with adenosylmethionine at base of reduced glutathione. Serum malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were routinely detected. Results After two to six (3.1±1.4) week treatment, serum ALT, AST and bilirubin levels in the observation group were (61.2±8.3)U/L, (54.5±7.4)U/L and (14.4±4.1)μmol/L, all significantly lower than [(86.5±11.5)U/L, (63.1±8.0)U/L and (21.5±5.4)μmol/L, respectively, P<0.05] in the control; serum prealbumin and cholinesterase levels were (205.5±1.9)mg/L and (5224.1±589.9)u/L, both significantly higher than [(188.5±34.2)mg/L and (4933.9±602.2)u/L, respectively, P<0.05], while serum total bile acids was (7.1±1.7)μmol/L, significantly lower than [(9.5±2.1)μmol/L, P<0.05] in the control; serum MDA level was (4.5±0.7)μmol/L, significantly lower than [(6.5±0.9)μmol/L, P<0.05], while serum SOD and GSH-Px levels were (83.1±7.9)U/L and (125.1±13.7)u/L, both significantly higher than [(75.9±7.2)U/L and (105.5±11.1) u/L, respectively, P<0.05] in the control group. Conclusion The short-term clinical efficacy of adenosylmethionine and reduced glutathione combination in treatment of patients with DILI is good, which could effectively inhibit inflammatory reactions and oxidative stress, and protect the liver functions.

Key words: Drug-induced liver injury, Adenosylmethionine, Reduced glutathione, Therapy